Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
TSMC Posts Record Q1 2026 Profits Driven by Surging AI Chip Demand 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Meta Is Building an AI Version of Mark Zuckerberg to Interact With Employees 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Baker Hughes Sells Waygate Technologies to Hexagon for $1.45 Billion 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
SAN DIEGO, June 01, 2017 -- Daré Bioscience, Inc., a privately-held, clinical-stage healthcare company advancing products for women's reproductive health, today announced that Sabrina Martucci Johnson, Daré Founder and CEO, will present at the LD Micro Invitational Conference on Wednesday, June 7, 2017, at 7:30 a.m. PST at the Luxe Sunset Bel Air Hotel in Los Angeles, California.
“Daré’s product candidate, Ovaprene®, is a clinical stage, non-hormonal contraceptive ring for monthly use,” said Ms. Johnson. “Since the approval of the birth control pill by the FDA in 1960, most innovation has focused on hormones. If approved, Ovaprene would address an unmet need because it is a non-hormonal monthly option. The only contraceptive ring on the market is a hormonal contraceptive ring, NuvaRing®, with 2016 sales of $777 million.”
About Daré Bioscience
Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products in women's reproductive health. Daré believes there is an unmet need in the United States, in other developed countries, and in developing countries, for innovative product candidates that expand options, improve outcomes and are easy to use. Product development in women's reproductive health is fragmented, creating a potential opportunity for Daré. Daré’s goal is to fill the gap by taking products from innovation through development. The Daré team is well-suited to ensure these products advance and are one day commercially available. The founders bring experience in global women's healthcare as well as success in prior ventures in funding, achieving regulatory approvals, partnering, and launching a number of products, including devices, therapeutics and diagnostics.
For more information on Daré, please visit www.darebioscience.com.
Contact: Sabrina Johnson 858-769-9145 [email protected]
